Publication:
Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients.

No Thumbnail Available

Date

2018-04-17

Authors

Pérez-Ramírez, Cristina
Cañadas-Garre, Marisa
Alnatsha, Ahmed
Villar, Eduardo
Valdivia-Bautista, Javier
Faus-Dáder, María José
Calleja-Hernández, Miguel Ángel

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Chemotherapy based on platinum compounds is the standard treatment for NSCLC patients with EGFR wild type, and is also used as second line in mutated EGFR patients. Nevertheless, this therapy presents poor clinical outcomes. ERCC1, ERCC2, XRCC1, MDM2, MTHFR, MTR, and SLC19A1 gene polymorphisms may contribute to individual variation in response and survival to platinum-based chemotherapy. The aim of this study was to investigate the influence of these polymorphisms on response and survival of NSCLC patients treated with platinum-based chemotherapy. A retrospective-prospective cohorts study was conducted, including 141 NSCLC patients. Polymorphisms were analyzed by PCR real-time with Taqman® probes. Patients with ERCC1 rs3212986-GG (p = 0.0268; OR = 2.50; CI95% = 1.12-5.69) and XRCC1 rs25487-GG (p = 0.0161; OR = 2.99; CI95% = 1.26-7.62) genotype showed significantly better ORR. Cox survival analysis revealed that patients carrying the MDM2 rs1690924-GG genotype (p = 0.0345; HR = 1.99; CI95% = 1.05-3.80) presented higher risk of death. Furthermore, carriers of MTR rs1805087-A alleles (p = 0.0060; HR = 8.91; CI95% = 1.87-42.42) and SLC19A1 rs1051266-AA genotype (p = 0.0130; HR = 1.74; CI95% = 1.12-2.68) showed greater risk of progression. No influence of ERCC1 rs11615, ERCC2 rs13181, ERCC2 rs1799793, XRCC1 rs1799782, MDM2 rs1470383, MTHFR rs1801131, and MTHFR rs1801133 on platinum-based chemotherapy clinical outcomes was found. In conclusion, our results suggest that ERCC1 rs3212986, XRCC1 rs25487, MDM2 rs1690924, MTR rs1805087, and SLC19A1 rs1051266 gene polymorphisms may significantly act as predictive factors in NSCLC patients treated with platinum-based chemotherapy.

Description

MeSH Terms

5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase
Aged
Biomarkers, Tumor
Carcinoma, Non-Small-Cell Lung
DNA Repair
DNA-Binding Proteins
Endonucleases
Female
Folic Acid
Humans
Male
Methylenetetrahydrofolate Reductase (NADPH2)
Middle Aged
Pharmacogenetics
Platinum
Prognosis
Proportional Hazards Models
Proto-Oncogene Proteins c-mdm2
Reduced Folate Carrier Protein
Survival Analysis
X-ray Repair Cross Complementing Protein 1
Xeroderma Pigmentosum Group D Protein

DeCS Terms

CIE Terms

Keywords

Citation